ALPHARETTA, Ga., May 19, 2016 /PRNewswire/ -- EndoChoice Holdings, Inc. (NYSE: GI) announced today the full market release of its Generation 3 Full Spectrum Endoscopy® (Fuse®) system. Fuse Generation 3 includes an ergonomically advanced control body, incorporating over 50 system enhancements and a novel Adaptive Matrix Imaging technology called Lumos™, that enables physicians to see more with enhanced clarity. The company is beginning sales and distribution of Generation 3 scopes in the United States, European Union, and other select markets.
Lumos Adaptive Matrix Imaging takes a revolutionary approach to enhance the view of the mucosal structures and vascular patterns in their natural color and the ability for "always-on" functionality via smart enhancement technology, making it the first advanced imaging solution designed to improve the entire procedure. Lumos is now launched in Europe with the CE mark, and is pending FDA clearance in the United States.
EndoChoice will highlight Fuse Generation 3 at Digestive Disease Week® (DDW®) in San Diego, California (Booth #4317), and at the SGNA™ 43rd Annual Course in Seattle, Washington. EndoChoice will display at these meetings May 22 to 24.
Commenting on the new product release, Dr. Booker Dalton, Gastroenterologist at Digestive Healthcare of Georgia, said "Fuse Generation 3 is a significant advancement of the Full Spectrum Endoscopy system. Fuse's new ergonomic design and system refinements greatly enhance the overall user experience. Coupled with its already impressive 330-degree field of view and published clinical value, Fuse is a game changer."
Mark Gilreath, Founder and CEO of EndoChoice, stated, "We are truly excited to bring Fuse Generation 3 and Lumos to the world of GI. With Generation 3, not only do GI's have an increased field of view to help detect lesions, they now have the ability to enhance anatomy like never before with Lumos Adaptive Matrix Imaging. We believe these advancements take the Fuse platform to an unprecedented level in endoscopic screening."
About DDW
Digestive Disease Week® (DDW) is the largest international gathering of physicians, researchers and academics in the fields of gastroenterology, hepatology, endoscopy and gastrointestinal surgery. Jointly sponsored by the American Association for the Study of Liver Diseases (AASLD), the American Gastroenterological Association (AGA) Institute, the American Society for Gastrointestinal Endoscopy (ASGE) and the Society for Surgery of the Alimentary Tract (SSAT), DDW take place May 21-24, 2016, at the San Diego Convention Center, San Diego, CA. The meeting showcases more than 5,000 abstracts and hundreds of lectures on the latest advances in GI research, medicine and technology. More information can be found at http://www.ddw.org
About SGNA
The Society of Gastroenterology Nurses and Associates, Inc. (SGNA™) 43rd Annual Course in Seattle is the premier education and networking event dedicated to gastroenterology and endoscopy nursing professionals. The event will take place May 22-24, 2016 in Seattle, Washington. More information can be found at HTTP://www.sgna.org/2016annualcourse
About EndoChoice
Based near Atlanta, Georgia, EndoChoice® (NYSE: GI) is a medtech company focused on the manufacturing and commercialization of platform technologies including endoscopic imaging systems, devices and infection control products and pathology services for specialists treating a wide range of gastrointestinal conditions, including colon cancer.
EndoChoice leverages its direct sales organization to serve more than 2,500 customers in the United States and works with distribution partners in 30 countries. The Company was founded in 2008 and has rapidly developed a broad and innovative product portfolio, which includes the Full Spectrum Endoscopy® (Fuse®) system. EndoChoice, Fuse, and Full Spectrum Endoscopy are registered trademarks of EndoChoice, Inc.
For more information, press only:
Company Contact:
David Gill, President & CFO 678-585-1040 david.gill@endochoice.com
Investor Contacts:
Nick Laudico or Zack Kubow The Ruth Group 646-536-7030 / 7020 nlaudico@theruthgroup.com zkubow@theruthgroup.com
EndoChoice® Announces FDA Clearance of its Orca™ Sterile, Single-Use Air/Water and Suction Valves Date : 05/23/2016 @ 12:47PM Source : PR Newswire (US) Stock : Endochoice Holdings, Inc. (GI) Quote : 4.2684 -0.2416 (-5.36%) @ 2:21PM EndoChoice® Announces FDA Clearance of its Orca™ Sterile, Single-Use Air/Water and Suction Valves
ALPHARETTA, Ga., May 23, 2016 /PRNewswire/ -- EndoChoice Holdings, Inc. (NYSE: GI) announced it received 510(k) clearance for its new Orca™ sterile, single-use air/water and suction valves for Olympus® 160, 180 and 190 Series flexible endoscopes.
Recently published clinical guidelines from Association for the Advancement of Medical Instrumentation (AAMI) and the Society of Gastroenterology Nurses and Associates (SGNA), state that reusable endoscopic accessories (e.g., air/water and suction valves) should be reprocessed together and stored with a specific endoscope as a unique set to ensure traceability.
By eliminating the need to clean and disinfect reusable valves, the single use Orca™ valves allow clinicians to adhere to these new guidelines while improving patient care and workflow efficiency.
The company will begin sales and distribution of the new valves in the United States, European Union, and other select markets.
EndoChoice will highlight the new sterile, single-use valves at Digestive Disease Week® (DDW®) in San Diego, California (Booth #4317), and at the SGNA™ 43rd Annual Course in Seattle, Washington.
EndoChoice will display at these meetings May 22 to 24.
Commenting on the announcement, Mark Gilreath, Founder and CEO of EndoChoice said, "EndoChoice has been dedicated to improving the standard of care for infection control since 2010, when it launched the Compliance EndoKit®, the first GI procedural kit designed to help clinicians standardize to good infection control practices.
The Orca™ sterile single use air/water and suction valves are an excellent addition to the Compliance EndoKit®, thus continuing to improve the standard of care in GI."
About EndoChoice
Based near Atlanta, Georgia, EndoChoice® (NYSE: GI) is a medtech company focused on the manufacturing and commercialization of platform technologies including endoscopic imaging systems, devices and infection control products and pathology services for specialists treating a wide range of gastrointestinal conditions, including colon cancer.
EndoChoice leverages its direct sales organization to serve more than 2,500 customers in the United States and works with distribution partners in 30 countries.
The Company was founded in 2008 and has rapidly developed a broad and innovative product portfolio, which includes the Full Spectrum Endoscopy® (Fuse®) system. EndoChoice, Fuse, and Full Spectrum Endoscopy are registered trademarks of EndoChoice, Inc.
For more information, press only:
Company Contact:
Ryan Moskowitz Senior Director, Marketing Communications EndoChoice 678-708-4403 ryan.moskowitz@endochoice.com
Investor Contacts:
Nick Laudico or Zack Kubow The Ruth Group 646-536-7030 / 7020 nlaudico@theruthgroup.com zkubow@theruthgroup.com
ALPHARETTA, Ga., May 19, 2016 /PRNewswire/ -- EndoChoice Holdings, Inc. (NYSE: GI) announced the full market release of its RescueNet™ retrieval device. Based upon the OmniLoop™ technology unveiled with the Boa® polypectomy snare, RescueNet's design also incorporates new ProMesh™ technology. RescueNet™ provides greater visibility and control with improved mesh strength, which allows for reliable and efficient foreign body removal. The company is beginning sales and distribution in the United States, European Union, and other select markets.
Since its recent introduction, RescueNet™ has been extremely well received by nurses and physicians. "The RescueNet is the best on the market today. It opens and closes in any position, adjustable, and works time after time. It never seems to wear out," stated Jerry Rayfield, GI Nurse Manager at Russell Medical Center, Alexander City, AL.
This year EndoChoice will be highlighting RescueNet™ in its booth at Digestive Disease Week (DDW®) in San Diego, California, and at the SGNA 43rd Annual Course in Seattle, Washington.
Commenting on the new product release, Mark Gilreath, Founder and CEO of EndoChoice said "This innovation is the result of our company's unique insights into the needs of GI caregivers to provide tools which improve the efficiency and effectiveness of their clinical procedures.
RescueNet™ is the perfect addition to our family of Rescue® retrieval devices and the EndoChoice® portfolio of polypectomy devices, which includes the Boa® polypectomy snare, Mako™ biopsy forceps, Neptune® injection needle, and the TrapEase® polyp trap."
About DDW
Digestive Disease Week® (DDW) is the largest international gathering of physicians, researchers and academics in the fields of gastroenterology, hepatology, endoscopy and gastrointestinal surgery.
Jointly sponsored by the American Association for the Study of Liver Diseases (AASLD), the American Gastroenterological Association (AGA) Institute, the American Society for Gastrointestinal Endoscopy (ASGE) and the Society for Surgery of the Alimentary Tract (SSAT), DDW take place May 21-24, 2016, at the San Diego Convention Center, San Diego, CA.
The meeting showcases more than 5,000 abstracts and hundreds of lectures on the latest advances in GI research, medicine and technology. More information can be found at http://www.ddw.org
About SGNA
The Society of Gastroenterology Nurses and Associates, Inc. (SGNA™) 43rd Annual Course in Seattle is the premier education and networking event dedicated to gastroenterology and endoscopy nursing professionals.
Based near Atlanta, Georgia, EndoChoice® (NYSE: GI) is a medtech company focused on the manufacturing and commercialization of platform technologies including endoscopic imaging systems, devices and infection control products and pathology services for specialists treating a wide range of gastrointestinal conditions, including colon cancer.
EndoChoice leverages its direct sales organization to serve more than 2,500 customers in the United States and works with distribution partners in 30 countries.
The Company was founded in 2008 and has rapidly developed a broad and innovative product portfolio, which includes the Full Spectrum Endoscopy® (Fuse®) system. EndoChoice, Fuse, and Full Spectrum Endoscopy are registered trademarks of EndoChoice, Inc.
For more information, press only:
Company Contact:
Ryan Moskowitz Senior Director, Marketing Communications EndoChoice 678-708-4403 ryan.moskowitz@endochoice.com
Investor Contacts:
Nick Laudico or Zack Kubow The Ruth Group 646-536-7030 / 7020 nlaudico@theruthgroup.com zkubow@theruthgroup.com
News 
Market Data 
Discover 
